4.6 Article

Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer

Journal

WORLD JOURNAL OF GASTROENTEROLOGY
Volume 20, Issue 42, Pages 15580-15589

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v20.i42.15580

Keywords

Position emission tomography/computed tomography; Pancreatic cancer; Diagnosis; Staging; Metabolic response

Funding

  1. Shanghai Municipal Health Bureau [XYQ2013090]
  2. Shanghai Young Physician Training Program
  3. Fudan University
  4. Huashan Hospital, Fudan University [2013QD21]
  5. National Natural Science Foundation of China [81071884]
  6. Research Fund for the Doctoral Program of Higher Education of China [20110071110065]

Ask authors/readers for more resources

Pancreatic cancer is one of the most common gastrointestinal tumors, with its incidence staying at a high level in both the United States and China. However, the overall 5-year survival rate of pancreatic cancer is still extremely low. Surgery remains the only potential chance for long-term survival. Early diagnosis and precise staging are crucial to make proper clinical decision for surgery candidates. Despite advances in diagnostic technology such as computed tomography (CT) and endoscopic ultrasound, diagnosis, staging and monitoring of the metabolic response remain a challenge for this devastating disease. Positron emission tomography/CT (PET/CT), a relatively novel modality, combines metabolic detection with anatomic information. It has been widely used in oncology and achieves good results in breast cancer, lung cancer and lymphoma. Its utilization in pancreatic cancer has also been widely accepted. However, the value of PET/CT in pancreatic disease is still controversial. Will PET/CT change the treatment strategy for potential surgery candidates? What kind of patients benefits most from this exam? In this review, we focus on the utility of PET/CT in diagnosis, staging, and assessment of resectability of pancreatic cancer. In addition, its ability to monitor metabolic response and recurrence after treatment will be emphasis of discussion. We hope to provide answers to the questions above, which clinicians care most about. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

An evaluation study of reported pancreatic adenocarcinoma risk-associated SNPs from genome-wide association studies in Chinese population

Xiaoyi Wang, Xiaoling Lin, Rong Na, Deke Jiang, Pengyin Zhang, Ji Li, Chen Jin, Deliang Fu, Jianfeng Xu

PANCREATOLOGY (2017)

Article Oncology

Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study

Nikolai A. Podoltsev, Xiaoyi Wang, Rong Wang, Jonathan N. Hofmann, Linda M. Liao, Amer M. Zeidan, Ruben Mesa, Xiaomei Ma

INTERNATIONAL JOURNAL OF CANCER (2020)

Letter Oncology

Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption

Nikolai A. Podoltsev, Xiaoyi Wang, Rong Wang, Jonathan N. Hofmann, Linda M. Liao, Amer M. Zeidan, Ruben Mesa, Xiaomei Ma

INTERNATIONAL JOURNAL OF CANCER (2020)

Article Gastroenterology & Hepatology

Single-nucleotide polymorphisms based genetic risk score in the prediction of pancreatic cancer risk

Xiao-Yi Wang, Hai-Tao Chen, Rong Na, De-Ke Jiang, Xiao-Ling Lin, Feng Yang, Chen Jin, De-Liang Fu, Jian-Feng Xu

WORLD JOURNAL OF GASTROENTEROLOGY (2020)

No Data Available